Luspatercept for early anemia after stem cell transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether luspatercept can help improve low red blood cell counts (anemia) that happens soon after a stem cell transplant. It is for people with blood cancers who have very low hemoglobin after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer and received a stem cell transplant from a donor.
- Your hemoglobin level is 60 g/L or less right after transplant.
- You are between 18 and 60 years old.
- You are able to do daily activities with little or no help (ECOG score 0-2).
- You can sign a consent form (or a family member can sign for you).
- You do not have uncontrolled infections, severe organ damage, or recent heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called luspatercept to see if it can help people who have low red blood cells (anemia) after a stem cell transplant for leukemia. It may improve your energy and reduce the need for blood transfusions.
This trial tests whether a drug called luspatercept can help your body produce red blood cells better after a bone marrow transplant for blood cancer. The goal is to reduce complications and improve recovery.
This trial tests if luspatercept can help improve red blood cell counts in people with a certain type of acute myeloid leukemia (AML) who have mild to moderate anemia after intensive chemotherapy. It is for patients with a lower-risk form of AML who have completed 1–3 cycles of high-dose consolidation therapy.
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
This trial tests a new medication called luspatercept to help patients whose red blood cells aren't recovering well after a bone marrow transplant for blood cancer. The goal is to see if it works better than the standard treatment (epoetin) to boost red blood cell production.
This trial tests a drug called luspatercept to see if it can raise hemoglobin levels in people with anemia caused by chronic kidney disease. It's for those whose current treatments aren't working well or who cannot use them.
Hear when a new HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.